PARSIPPANY, N.J. (AP) – Watson Pharmaceuticals Inc. said that the Food and Drug Administration approved its generic version of the osteoarthritis and rheumatoid arthritis drug Arthrotec.
Arthrotec is marketed by G.D. Searle. It is used to treat symptoms of osteoarthritis and rheumatoid arthritis in patients who are at high risk for ulcers if treated with non-steroidal anti-inflammatory drugs for arthritis and pain.
Watson said it will start selling its generic drug during the fourth quarter. It said U.S. sales of Arthrotec totaled about $130 million over the 12-month period ended May 31.
Date: July 11, 2012
Source: Associated Press
Filed Under: Drug Discovery